araag2/HINT huggingface dataset:
Clinical trial NCT00463788 (phase 2, status: completed)
Conditions: breast neoplasm
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cetuximab, cisplatin, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of metastatic breast cancer (Stage IV)

          -  Estrogen Receptor [ER] negative, PgR negative and HER2 less than 3+ expression by
             immunohistochemistry (IHC)

          -  No more than 1 prior chemotherapy received for treating this metastatic breast cancer

          -  No more than 1 prior anthracycline and/or taxane regimen (either adjuvant or
             metastatic setting)

          -  Other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  Prior platinum agent

          -  Prior mitomycin

          -  Known history of brain metastases

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT01020799 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: azd7268, escitalopram, placebo capsules, placebo tablets
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed, written, and dated Informed Consent prior to any study specific
             procedures

          -  Documented primary clinical diagnosis meeting criteria from the DSM-IV, Text Revision
             (APA 2000) for any of the following:

          -  296.2x Major Depressive Disorder, Single Episode, or

          -  296.3x Major Depressive Disorder, Recurrent

        Exclusion Criteria:

          -  Patients with a secondary DSM-IV Axis I disorder other than GAD or social anxiety
             disorder (as assessed by MINI), provided the primary diagnosis is MDD. This diagnosis
             should have been made at least 6 months before enrollment

          -  Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the
             patient's current psychiatric status

          -  Patients whose current episode of depression started less than 4 weeks before
             enrollment
Clinical trial NCT00584740 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: ain457, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated prematurely after futility criterion was met at planned interim
    analysis of 41 patients.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female; 18-75 years old

          -  Diagnosis of Crohn's disease for at least 3 months prior to screening

          -  Confirmation of Crohn's disease by endoscopic or imaging examination

          -  Moderately active Crohn's disease at baseline, defined as:

          -  CDAI ≥220 and ≤450

          -  Active disease despite prior treatment with corticosteroids for at least 2 weeks, or
             immunosuppressants for at least 3 months. Treatment with azathioprine, 6-MP or MTX is
             allowed but must have been on a stable dose for at least 10 weeks, corticosteroids are
             allowed but must have been on a stable doses of prednisolone not exceeding 40 mg for
             two weeks prior to baseline. Immunosuppressants other than those listed above, such as
             cyclosporine, tacrolimus and mycophenolate, are not allowed and must be stopped
             (wash-out periods defined in the protocol);

        Exclusion Criteria:

          -  Body Mass Index >34

          -  Positive PPD tuberculin skin test or QuantiFeron test

          -  Any subject with evidence of active pulmonary disease or evidence of latent
             tuberculosis or fungal infection at screening or within past 3 months

          -  Symptoms associated with active bowel structuring disease and pre-stenotic dilation on
             radiographs

          -  Fistulizing disease if complicated by sepsis and/or untreated abscess

          -  Multiple bowel surgeries and clinically important short bowel syndrome defined as an
             inability to maintain caloric intake

          -  Use of certain medications as specified in the protocol

          -  Clinical improvement due to other Crohn's therapy

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01190475 (phase 2, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: active treatment with a high dose of bgs649, active treatment with a low dose of bgs649, placebo treatment to blind study
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal women with documented moderate to severe endometriosis. Occurrence of
             three sequential menstrual cycles of 24-35 days duration prior to enrollment.

          -  Laparoscopically proven diagnosis of moderate to severe endometriosis (diagnosed
             within the past 10 years before screening).

          -  Patients not planning to become pregnant within one year after the screening visit and
             willing to use two effective methods of non-hormonal, barrier birth control for the
             duration of the study or who are surgically sterile.

          -  Patients must have a score of at least 4 on the numerical rating scale (NRS) for one
             of the following three pain measurements: pelvic pain, menstrual pain and dyspareunia

        Exclusion Criteria:

          -  Estrogen replacement therapy using either prescription medications or
             estrogen-containing OTC nutritional/herbal supplements such as soy extracts or topical
             estrogens.

          -  Aromatase inhibitor therapy (includes Femara (letrozole), Aromasin (exemestane) or
             Arimidex (anastrozole) within the past 12 months.

          -  Oral bisphosphonate therapy (i.e. Fosamax (alendronate)) within the past 6 months or
             intravenous bisphosphonate (i.e., Reclast, pamidronate) < 15 months from screening.

          -  Systemic glucocorticoid therapy within the past 4 weeks.

          -  Contra-indications to oral contraceptive use.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01377844 (phase 2, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: egt0001442, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects ≥18 years old

          -  Diagnosed with type 2 diabetes

          -  Body mass index (BMI) ≤ 45 kg/m2

          -  HbA1c between 7 and 10% (inclusive) at screening

          -  FPG <250 mg/dL at screening for subjects not treated with oral anti-diabetic therapies
             or FPG <240 mg/dL at screening for subjects treated with anti-diabetic therapies

          -  Diabetes currently treated with diet and exercise only or diet and exercise along with
             one approved oral anti-diabetic agent

          -  If taking anti-diabetic medication, dose and regimen must be stable for past 3 months

          -  If taking anti-hypertensive medication, dose and regimen must be stable for past 3
             months

          -  If taking lipid modifying therapy, dose and regimen must be stable for past 3 months

          -  Blood glucose <250 mg/dL based on finger stick blood glucose for all subjects at
             randomization

        Exclusion Criteria:

          -  Hemoglobinopathy that affects HbA1c measurement

          -  Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor
             based therapy)

          -  Genitourinary tract infection within 6 weeks of screening

          -  Greater than 2 episodes of genitourinary tract infection in the past year

          -  History of kidney stones, bladder malfunction or other significant risk factor for
             urinary tract infections

          -  eGFR, as calculated by the modification of diet in renal disease study equation
             (MDRD), < 50 mL/min/1.73 m2

          -  Abnormal tests of liver function ALT, AST or bilirubin ≥ 3x ULN

          -  Diagnosis of retinopathy or significant nephropathy (eGFR < 50 mL/min/1.73 m2

          -  Uncontrolled hypertension (systolic blood pressure >160 or diastolic blood pressure
             >95)

          -  Not willing to use effective birth control, if female with child-bearing potential

          -  Life expectancy < 2 years

          -  New York Heart Association (NYHA) Class 4 heart failure

          -  Sera positive of HCV, HIV, or positive on drug screen

          -  Currently participating in another interventional trial

          -  Previous treatment with EGT0001442 or EGT0001474

          -  Not able to comply with the study scheduled visits
Clinical trial NCT00529204 (phase 2, status: terminated)
Conditions: diabetes complications, fatty liver
ICD codes: E10.9, E11.9, E13.9, E10.8, E11.8, E13.8, E08.9, K70.0, K76.0
Drugs: exenatide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age >18 years, < 70 years, inclusive

          -  Type 2 diabetes on stable doses of sulfonylurea and/or metformin

          -  Body mass index > 35 kg/m2

          -  Presumed diagnosis of NAFLD based upon

          -  an ALT > 1.5 times the upper limit of reference range,

          -  no evidence of other causes of liver disease and

          -  ultrasound findings compatible with fatty liver

        Exclusion Criteria:

          -  Clinical signs of cirrhosis as evidenced by any of the following

          -  spider angiomata,

          -  splenomegaly,

          -  ascites

          -  jaundice

          -  encephalopathy

          -  INR > 1.2

          -  Platelet count < 100,000/ml

          -  Serum albumin < 3.0 g/dL

          -  Other liver disease including chronic viral hepatitis (B or C), alcohol abuse,
             hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's
             disease, primary sclerosing cholangitis or primary biliary cirrhosis.

          -  Current use of > 20 g of alcohol per day or unwillingness to avoid alcohol during the
             course of the study

          -  Treatment with a thiazolidinedione or exenatide within 6 months of enrolling in the
             study

          -  AST or ALT > 10 times the upper limit of normal

          -  Treatment with any investigational drug within 4 weeks of enrollment

          -  Pre-menopausal, fertile women unwilling to use contraceptives during the study period.

          -  Pregnancy or lactation

          -  Initiation or change in dose of hypolipidemic drugs (statins, niacin, cholestyramine
             are allowed) within 6 months of enrollment

          -  Use of anticoagulation, bleeding disorders or other contraindications to liver biopsy
Clinical trial NCT00680940 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel & cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Histologically or cytologically confirmed Non-Small Cell Cancer, Stage IIIB or IV.

          -  Age should be 18 years or above.

          -  ECOG should be in 0-1 range.

          -  Absolute neutrophil count ≥ 1,00,000/mm3

          -  hemoglobin ≥ 9.0g/dL

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)range of institution (5times ULN if
             liver metastasis present).

          -  bilirubin not greater than 1.5 times ULN range of institution (3 times ULN if liver
             involvement).

          -  Creatinine ≤ upper limit of normal (ULN) range of institution.

          -  Negative pregnancy test for women of child bearing potential prior to entry into the
             trial.

        Exclusion Criteria:

          -  Patient who have cytotoxic chemotherapy or radiotherapy prior to entering the study

          -  Patient with systematic brain metastasis.

          -  History of allergic reaction attributed to paclitaxel, cisplatin or mycobacterium w or
             any of their ingredients.

          -  Pregnant women or nursing women.

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements.

          -  HIV positive patients.

          -  Previous splenectomy.
Clinical trial NCT00698230 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: incb013739, incb013739, incb013739, incb013739, incb013739, placebo comparator matching incb013739, metformin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Established diagnosis of Type 2 Diabetes

          -  Stable dose of metformin for more than 8 weeks

        Exclusion Criteria:

          -  Subjects with Addison's disease or Cushing's Syndrome

          -  Type 1 diabetes mellitus or secondary forms of diabetes

          -  Subjects with uncontrolled thyroid disease

          -  History of renal impairment
Clinical trial NCT00268710 (phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically/cytologically proven prostate adenocarcinoma

          -  Progression or non response with previous chemotherapy regimen (excluding Taxotere®)

          -  Received previous mitoxantrone/prednisone or one other chemotherapy regimen including
             emcyt +/- vinblastine

          -  Castration levels of testosterone (<50 ng/dL )

          -  ECOG performance status 0-2

          -  Laboratory requirements :

               1. Hematology:

                    -  Neutrophils ≥ 1.5 x 10^9/L

                    -  Hemoglobin > 10 g/dL (prior transfusion permitted).

                    -  Platelets ≥ 100 x 10^9/L

               2. Hepatic function:

                    -  Total bilirubin < the upper-normal limit of the institution.

                    -  ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the upper-normal limit of the
                       institution.

               3. Renal function:

                    -  Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1)

          -  No severe or uncontrolled disease

        Exclusion Criteria

          -  Chemotherapy within the last 4 weeks

          -  Anti-androgen therapy within the last 4 weeks.

          -  Prior malignancy except the following: adequately treated non-melanomatous skin cancer
             and superficial bladder cancer from which the patient has been disease-free for >2
             years.

          -  Concurrent treatment with other experimental drugs. Participation in another clinical
             trial with any investigational drug within 30 days prior to study screening.

          -  Treatment with any other anti-cancer therapy (except LHRH agonists) including any
             prescribed compounds and/or OTC products for the treatment of prostate cancer must be
             stopped prior to study entry.

          -  Other serious illness, psychiatric or medical condition that would not permit the
             patient to be managed according to the protocol including active uncontrolled
             infection and significant cardiac dysfunction.
Clinical trial NCT00320255 (phase 2, status: completed)
Conditions: thrombosis, cancer, pulmonary embolism
ICD codes: I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: apixaban, placebo
SMILES: COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Recipients of either first- or second-line chemotherapy for advanced or metastatic
             lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer or myeloma,
             selected lymphomas, or cancer of unknown origin

          -  Able to begin study medication ≤6 weeks of starting either first- or second-line
             chemotherapy.

          -  Expected course of chemotherapy must have been ≥ 90 days after the start of
             chemotherapy

          -  Per Protocol Amendment 5, patients receiving bevacizumab were eligible to participate,
             provided that bevacizumab was used for indications approved by local country law

        Key Exclusion Criteria:

          -  Women who are pregnant, breastfeeding

          -  History of deep vein thrombosis or pulmonary embolism

          -  Active bleeding or at high risk of bleeding

          -  Metastatic brain cancer

          -  Familial bleeding diathesis

          -  Serious hemorrhage requiring hospitalization, transfusion, or surgical intervention
             within 4 weeks of study entry

          -  Expected survival <6 months or an Eastern Cooperative Oncology Group performance
             status ≥3.

          -  Candidates for bone marrow transplantation within the 12-week treatment period or
             30-day follow-up period

          -  Uncontrolled hypertension (systolic blood pressure >200 mm Hg and/or diastolic blood
             pressure >110 mm Hg

          -  Coagulopathy (international normalized ratio >1.5 or platelet count <100*10^9/L) if
             not yet receiving chemotherapy or <50*10^9/L if receiving chemotherapy). Platelet
             count must have been >100*10^9/L before starting study medication

          -  One or more of the following: alanine aminotransferase >3 times the upper limit of
             normal (ULN), total bilirubin >2*ULN, or calculated creatinine clearance <30 mL/min.
Clinical trial NCT00564928 (phase 2, status: completed)
Conditions: prostate cancer, prostatic neoplasms, cancer of the prostate
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, B38.81, N42.31, Z87.430, N40.0, N40.1, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ipi-504
SMILES: CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(O)=CC(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)=C2O
Eligibility criteria:

        Inclusion Criteria:

          -  Adenocarcinoma of the prostate

          -  Resolution of acute toxic side effects of prior chemotherapy

          -  Castration resistant disease despite ongoing chemical or surgical castration

          -  ECOG 0-1

          -  PSA greater than or equal to 2

          -  Group A -

               -  No Prior treatment for prostate cancer with cytotoxic chemotherapy (neoadjuvant,
                  adjuvant treatment permitted if more than 2 years out)

          -  Group B

               -  Radiographic evidence of metastatic disease

               -  Prior tx with docetaxel-minimum of 2 cycles with progression by RECIST or PSA or
                  intolerant of tx

               -  Maximum of 3 prior chemotherapies

        Exclusion Criteria:

          -  Small cell carcinoma of the prostate

          -  Treatment within 2 weeks with approved, investigational, or small molecule

          -  Treatment within 4 weeks with biologic or external beam radiation

          -  ANC <1,500 cells m3; Platelets <100,000 mm3; Hemoglobin <9.0g/dL

          -  AST/ALT >2.5 ULN

          -  Serum creatinine >3.0mg/dL

          -  Active keratitis or keratoconjunctivitis

          -  Previous treatment with 17-AAG, DMAG; or any other HSP-90 inhibitor

          -  Baseline Qtc >450 mses
Clinical trial NCT01062971 (phase 2, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: dorzolamide-timolol-brimonidine
SMILES: CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects of either sex and any race with open-angle glaucoma or ocular
             hypertension;

          -  Visual acuity of 20/40 to 20/80 or better (Snellen equivalent).

        Exclusion Criteria:

          -  Clinically relevant ophthalmic or systemic conditions may be excluded.
Clinical trial NCT00053014 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclosporine, fludarabine, mycophenolate mofetil
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Morphologically confirmed acute myeloid leukemia (AML) (within 180 days of diagnosis)
             OR

          -  Secondary AML (secondary to myelodysplastic syndromes (MDS) or to prior leukemogenic
             therapy)

          -  Must have A1 marrow, B1 blood, and C1 extramedullary disease status

          -  Must have received prior remission induction chemotherapy

          -  Must have a genotypically HLA-identical sibling donor available that is not a
             monozygotic identical twin

          -  No M3 AML or blastic transformation of chronic myelogenous leukemia

          -  If history of CNS leukemia, no leukemia cells in CNS by lumbar puncture within past 7
             days

          -  Must be concurrently enrolled on protocols SWOG-9007 and SWOG-S9910

        PATIENT CHARACTERISTICS:

        Age

          -  55 to 69

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other malignancy within the past 2 years except for the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Carcinoma in situ of the cervix

               -  Adequately treated stage I or II cancer in complete remission

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior allogeneic hematopoietic stem cell transplantation

        Chemotherapy

          -  See Disease Characteristics

          -  Prior consolidation therapy allowed

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Prior organ transplantation allowed provided not concurrently receiving
             immunosuppressive therapy